Optimizing Antiemetic Strategies Across Phases of Chemotherapy-Induced Nausea and Vomiting: Real-World Evidence in Breast Cancer
Current Oncology · 2026
DOI: 10.3390/curroncol33020078 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, 2026. Verfasst von Akif Doğan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, University of Health Sciences, Sancaktepe Şehit İlhan Varank Training Research Hospital, Istanbul 34785, Turkey. Hauptthemen laut MEDLINE: Vomiting, Nausea, Breast Neoplasms, Antiemetics. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Chemotherapy-induced nausea and vomiting (CINV) remains one of the significant challenges in oncology despite guideline-based prophylaxis, particularly in patients receiving highly emetogenic chemotherapy (HEC). While neurokinin-1 (NK-1) receptor antagonists are established as a key component of standard antiemetic regimens, evidence of their phase-specific effectiveness in real-world, homogeneous patient populations remains limited. This study aimed to determine which antiemetic regimen provides optimal control in each CINV phase to support a tailored prophylactic approach.
Methods
This single-center, retrospective, real-world study included 260 female patients with stage II–III breast cancer receiving anthracycline–cyclophosphamide-based HEC. All patients had similar demographic and clinical characteristics, forming a relatively homogeneous cohort. Each received a triple antiemetic regimen consisting of a 5-HT3 receptor antagonist, dexamethasone, and an NK-1 receptor antagonist (either a single-dose intravenous fosaprepitant or a 3-day oral aprepitant). Complete response (no vomiting and no rescue therapy) and no-vomiting rates were assessed in the acute (0–24 h), delayed (24–120 h), and overall (0–120 h) phases.
Results
In this relatively homogeneous cohort of high-risk patients, fosaprepitant-based prophylaxis achieved better symptom control during the acute phase, whereas aprepitant-based regimens were more effective in the delayed and overall phases. These findings suggest phase-specific variations in antiemetic effectiveness that reflect pharmacokinetic and administration-route differences rather than population heterogeneity.
Conclusions
This real-world analysis demonstrates that antiemetic effectiveness varies by CINV phase, even within a relatively homogeneous, high-risk patient cohort. The results highlight the importance of phase-tailored prophylactic strategies to optimize symptom control and improve patient quality of life in highly emetogenic chemotherapy settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, University of Health Sciences, Sancaktepe Şehit İlhan Varank Training Research Hospital, Istanbul 34785, Turkey.
- Department of Family Medicine, University of Health Sciences, Sancaktepe Şehit İlhan Varank Training and Research Hospital, Istanbul 34785, Turkey.
- Department of Medical Oncology, University of Health Sciences, Kartal Lütfi Kırdar City Hospital, Istanbul 34865, Turkey.
ORCID-Profile: Akif Doğan, Hande Nur Erölmez, Goncagül Akdağ, Sedat Yıldırım, Özlem Nuray Sever
Zitieren
APA
Doğan, A., Erölmez, H. N., Akdağ, G., Yıldırım, S., & Sever, Ö. N. (2026). Optimizing Antiemetic Strategies Across Phases of Chemotherapy-Induced Nausea and Vomiting: Real-World Evidence in Breast Cancer. Current Oncology. https://doi.org/10.3390/curroncol33020078
Vancouver
Doğan A, Erölmez HN, Akdağ G, Yıldırım S, Sever ÖN. Optimizing Antiemetic Strategies Across Phases of Chemotherapy-Induced Nausea and Vomiting: Real-World Evidence in Breast Cancer. Current Oncology. 2026. doi:10.3390/curroncol33020078
BibTeX
@article{Doan2026,
author = {Doğan, Akif and Erölmez, Hande Nur and Akdağ, Goncagül and Yıldırım, Sedat and Sever, Özlem Nuray},
title = {Optimizing Antiemetic Strategies Across Phases of Chemotherapy-Induced Nausea and Vomiting: Real-World Evidence in Breast Cancer},
journal = {Current Oncology},
year = {2026},
doi = {10.3390/curroncol33020078}
}
EUVIMED